Pharmaceuticals company Marksans Pharma announced Q1FY26 results Operating revenue stood at Rs 620 crore, up by 5% YoY, driven mainly by growth in the US market from new product launches in the gastrointestinal, pain management, and digestive health segments. Gross profit stood at Rs 358.2 crore, up by 8.9% YoY, with a gross margin expansion of 209 bps YoY to 57.8%. Gross margin improved with the liquidation of higher-cost inventories and benefits from softening input costs. EBITDA stood at Rs 100.1 crore, with a margin of 16.1%. EPS was at Rs 1.3. Mark Saldanha, Managing Director, said: “While Q1FY26 was a seasonally soft quarter, we delivered year-on-year revenue growth of 5%, while gross profit increased by 8.9%. This was supported by successful new product launches in the US markets and the easing of raw material costs. While EBITDA and net profit margins were impacted by ramp-up costs, a one-time ECL provision for the emerging market division, and forex adjustments, these are transient and do not affect the fundamental momentum of our business. We are already seeing encouraging early signs of demand recovery in key markets such as the US, the UK, and Australia. With the Goa facility integration nearing completion, we are now sharply focused on scaling capacity, enhancing operational efficiency, and unlocking synergies. Our execution discipline, combined with a robust pipeline and expanding market presence, positions us well to deliver sustainable, long-term value. We remain committed to driving growth, improving returns, and creating enduring value for our stakeholders in FY26 and beyond.” Result PDF
Conference Call with Marksans Pharma Management and Analysts on Q4FY25 & Full Year Performance and Outlook. Listen to the full earnings transcript.
Pharmaceuticals company Marksans Pharma announced Q4FY25 & FY25 results Q4FY25 Financial Highlights: Operating revenue stood at Rs 708.5 crore., up by 26.5% YoY driven growth across key markets, led by US region Gross profit stood at Rs 383.2 crore., up by 32.1% YoY, with a gross margin expansion of 228 bps YoY to 54.1%. Growth is attributed to softening of raw material prices and a better product mix. EBITDA stood at Rs 125.8 crore. up by 14.7% YoY, with a margin of 17.8% EPS is at Rs 2.0, an incroreease of 15.7% FY25 Financial Highlights: Operating revenue stood at Rs 2,622.8 crore., up by 20.5% YoY driven by growth across all markets US business grew by 34.7% YoY UK & Europe grew by 9.2% YoY Australia & New Zealand grew by 15.5% YoY Gross profit came in at Rs 1,479.1 crore., up by 29.8% YoY, with a gross margin of 56.4% EBITDA stood at Rs 528.6 crore., up by 15.3%, with an EBITDA margin of 20.2% EPS grew by 21.3% YoY to Rs 8.4 Mark Saldanha, Managing Director of the Company said “We are pleased to announce another year of robust performance; we have achieved highest ever annual revenues and profits. In FY25, we witnessed strong performance across all our markets, the US market has been a key growth driver with 35% YoY increase in revenue. Our OTC segment’s performance is at all-time high, crossing Rs 2000 crore in revenue, a testament to our focus and execution on expanding the OTC product pipeline. Looking forward, we continue to strengthen our foundation by increasing the capacity and strengthening our product pipeline. We are optimistic about building on this momentum and create more value for our stakeholders in the coming years” Result PDF
Conference Call with Marksans Pharma Management and Analysts on Q3FY25 Performance and Outlook. Listen to the full earnings transcript.
Pharmaceuticals company Marksans Pharma announced Q3FY25 results Operating revenue stood at Rs 681.8 crore, up by 16.3% YoY driven growth across key markets, led by US region. Gross profit stood at Rs 383.5 crore, up by 22.4% YoY, with a gross margin expansion of 279 bps YoY to 56.2%. Growth is attributed to softening of raw material prices and a better product mix. EBITDA stood at Rs 138.8 crore up by 4.3% YoY, with a margin of 20.4%. EPS grew by 25.5% YoY to Rs 2.3. Mark Saldanha, Managing Director of the Company said: “We are delighted to announce an all-time high quarterly PAT, driven by robust growth of 16.3% YoY in Q3 revenue. Revenue growth was led by the US region, which witnessed 37% YoY growth, followed by UK, which improved during the quarter. Improved product mix and softer raw material prices compared to the previous year led to gross margin expansion of 279bps YoY. We witnessed some headwinds in terms of EBITDA margin due to our investments in the acquired facility and increased freight costs during the quarter. Looking ahead, we anticipate growth to continue in the coming quarters augmented by planned new launches and further ramp up of the TEVA facility.” Result PDF